Chronic myelomonocytic leukemia.

Abstract:

:Thirty adult patients with CMML were evaluated to determine prognostic factors that might have an impact on conversion to acute leukemia and survival. Neither leukocyte count nor monocyte count correlated with survival. The median survival for all 30 cases was 41 months. Patients with less than 5% marrow blasts had a median survival of 60 months but those with 5-20% blasts had only a 9-month median survival.

journal_name

Leukemia

journal_title

Leukemia

authors

Storniolo AM,Moloney WC,Rosenthal DS,Cox C,Bennett JM

subject

Has Abstract

pub_date

1990-11-01 00:00:00

pages

766-70

issue

11

eissn

0887-6924

issn

1476-5551

journal_volume

4

pub_type

杂志文章

相关文献

LEUKEMIA文献大全
  • Detection of residual proliferating leukemic cells by fluorescence in situ hybridization in CML patients in complete remission after interferon treatment.

    abstract::Interferon-alpha produces a complete hematologic and cytogenetic remission in approximately 20% of patients with chronic myelogenous leukemia (CML). In this study, we applied fluorescent in situ hybridization (FISH) methodology to examine the possibility that a low level of proliferating Philadelphia-chromosome-positi...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Zhao L,Kantarjian HM,Van Oort J,Cork A,Trujillo JM,Liang JC

    更新日期:1993-02-01 00:00:00

  • Characteristics of t(8;21) acute myeloid leukemia (AML) with additional chromosomal abnormality: concomitant trisomy 4 may constitute a distinctive subtype of t(8;21) AML.

    abstract::t(8;21)(q22;q22) is the most frequently observed karyotypic abnormality associated with acute myeloid leukemia (AML), especially in FAB M2. Clinically, this type of AML often shows eosinophilia and has a high complete remission rate with conventional chemotherapy. t(8;21) AML is also frequently associated with additio...

    journal_title:Leukemia

    pub_type: 杂志文章,多中心研究

    doi:10.1038/sj.leu.2402871

    authors: Nishii K,Usui E,Katayama N,Lorenzo F 5th,Nakase K,Kobayashi T,Miwa H,Mizutani M,Tanaka I,Nasu K,Dohy H,Kyo T,Taniwaki M,Ueda T,Kita K,Shiku H

    更新日期:2003-04-01 00:00:00

  • Flow cytometric analysis of intercellular adhesion between B-cell precursor acute lymphoblastic leukemic cells and bone marrow stromal cells.

    abstract::The growth of B-cell precursor acute lymphoblastic leukemic (BCP ALL) cells in vitro is dependent on interactions with bone marrow (BM) stromal cells. We have recently demonstrated that the rate of cell division of BCP ALL cells increases when cultured in direct contact with BM stromal cells. In this study we describe...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Ashley DM,Bol SJ,Tucker DP,Waugh CM,Kannourakis G

    更新日期:1995-01-01 00:00:00

  • Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome.

    abstract::We investigated the hypothesis that gemtuzumab ozogamicin (GO), an anti-CD33 immunotoxin would improve the efficacy of fludarabine/melphalan as a preparative regimen for allogeneic hematopoietic stem cell transplantation (HSCT) in a phase I/II trial. Toxicity was defined as grades III-IV organ damage, engraftment fail...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2405014

    authors: de Lima M,Champlin RE,Thall PF,Wang X,Martin TG 3rd,Cook JD,McCormick G,Qazilbash M,Kebriaei P,Couriel D,Shpall EJ,Khouri I,Anderlini P,Hosing C,Chan KW,Andersson BS,Patah PA,Caldera Z,Jabbour E,Giralt S

    更新日期:2008-02-01 00:00:00

  • Pediatric acute myelogenous leukemia cells express IL-6 receptors and are sensitive to a recombinant IL6-Pseudomonas exotoxin.

    abstract::We have studied IL-6 receptor (IL-6R) expression on AML cells from 15 pediatric patients by immunocytochemistry/flow cytometry, reverse-transcription polymerase chain reaction, and Scatchard analysis. High-affinity IL-6R were detected on leukemic cells from 12 (80%) patients. Binding sites per cell ranged from 140 to ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2400914

    authors: Boayue KB,Gu L,Yeager AM,Kreitman RJ,Findley HW

    更新日期:1998-02-01 00:00:00

  • A proof of concept phase I/II pilot trial of LSD1 inhibition by tranylcypromine combined with ATRA in refractory/relapsed AML patients not eligible for intensive therapy.

    abstract::All-trans-retinoic acid (ATRA) is highly active in acute promyelocytic leukemia but not in other types of acute myeloid leukemia (AML). Previously, we showed that ATRA in combination with Lysine-specific demethylase 1 (LSD1) inhibition by tranylcypromine (TCP) can induce myeloid differentiation in AML blasts. This pha...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-020-0892-z

    authors: Wass M,Göllner S,Besenbeck B,Schlenk RF,Mundmann P,Göthert JR,Noppeney R,Schliemann C,Mikesch JH,Lenz G,Dugas M,Wermke M,Röllig C,Bornhäuser M,Serve H,Platzbecker U,Foerster KI,Burhenne J,Haefeli WE,Müller LP,Bind

    更新日期:2020-06-19 00:00:00

  • Monocytic involvement by monosomy 7 preceded acute myelomonocytic leukemia in a patient with myelodysplastic syndrome.

    abstract::Novel techniques were used to detect which cell lineages were affected by monosomy 7 in a patient who had myelodysplastic syndrome and later developed acute leukemia. The patient had had paroxysmal nocturnal hemoglobinuria for 20 years before developing refractory anemia with excess of blasts. Cytogenetic analysis at ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Kere J,Knuutila S,Ruutu T,Leskinen R,de la Chapelle A

    更新日期:1988-02-01 00:00:00

  • Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis.

    abstract::We explored the association between bone marrow plasma cells (BMPCs) and disease presentation and outcome among 1574 AL patients. Three BMPC groups were formulated: <5% (n = 231, 15% of study population), 5-19% (n = 1045, 66%), and ≥20% (n = 298, 19%). Heart and renal involvement were more and less prevalent, respecti...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-019-0655-x

    authors: Muchtar E,Gertz MA,Kourelis TV,Sidana S,Go RS,Lacy MQ,Buadi FK,Dingli D,Hayman SR,Kapoor P,Leung N,Fonder A,Hobbs M,Lisa Hwa Y,Gonsalves W,Warsame R,Russell S,Lust JA,Lin Y,Zeldenrust S,Rajkumar SV,Kyle RA,Kum

    更新日期:2020-04-01 00:00:00

  • Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936.

    abstract::In a European BIOMED-2 collaborative study, multiplex PCR assays have successfully been developed and standardized for the detection of clonally rearranged immunoglobulin (Ig) and T-cell receptor (TCR) genes and the chromosome aberrations t(11;14) and t(14;18). This has resulted in 107 different primers in only 18 mul...

    journal_title:Leukemia

    pub_type: 杂志文章,多中心研究,评审

    doi:10.1038/sj.leu.2403202

    authors: van Dongen JJ,Langerak AW,Brüggemann M,Evans PA,Hummel M,Lavender FL,Delabesse E,Davi F,Schuuring E,García-Sanz R,van Krieken JH,Droese J,González D,Bastard C,White HE,Spaargaren M,González M,Parreira A,Smith JL,Mor

    更新日期:2003-12-01 00:00:00

  • Clinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with Response-Adapted therapy.

    abstract::To determine the clinical significance of minimal residual disease (MRD) in patients with prognostically relevant subtypes of childhood acute lymphoblastic leukemia (ALL), we analyzed data from 488 patients treated in St Jude Total Therapy Study XV with treatment intensity based mainly on MRD levels measured during re...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2016.234

    authors: Pui CH,Pei D,Raimondi SC,Coustan-Smith E,Jeha S,Cheng C,Bowman WP,Sandlund JT,Ribeiro RC,Rubnitz JE,Inaba H,Gruber TA,Leung WH,Yang JJ,Downing JR,Evans WE,Relling MV,Campana D

    更新日期:2017-02-01 00:00:00

  • Basic fibroblast growth factor (bFGF) upregulates the expression of bcl-2 in B cell chronic lymphocytic leukemia cell lines resulting in delaying apoptosis.

    abstract::Basic fibroblast growth factor (bFGF) is a pleiotropic cytokine which has recently been shown to delay fludarabine-induced apoptosis in B cell chronic lymphocytic leukemia (B-CLL) cells. To investigate the potential mechanism of bFGF-mediated delay of apoptosis, two EBV-transformed B prolymphocytic cell lines (JVM-2, ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2400556

    authors: König A,Menzel T,Lynen S,Wrazel L,Rosén A,Al-Katib A,Raveche E,Gabrilove JL

    更新日期:1997-02-01 00:00:00

  • Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia.

    abstract::Thiopurine methyltransferase (TPMT) catalyses the S-methylation of thiopurines, including 6-mercaptopurine and 6-thioguanine. TPMT activity exhibits genetic polymorphism, with about 1/300 inheriting TPMT deficiency as an autosomal recessive trait. If treated with standard doses of thiopurines, TPMTdeficient patients a...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/sj.leu.2401723

    authors: McLeod HL,Krynetski EY,Relling MV,Evans WE

    更新日期:2000-04-01 00:00:00

  • Determination of clonality in patients who present with diagnostic dilemmas: a laboratory experience and review of the literature.

    abstract::Identification of rearrangements in the immunoglobulin heavy chain (IgH), T cell receptor (TCR) and other genes assists in the classification of hemopoietic disorders. This study reviews a 5 year experience of genotyping as an assessment of clonality in a central referral laboratory. Patients were referred for assessm...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/sj.leu.2400678

    authors: Rockman SP

    更新日期:1997-06-01 00:00:00

  • The Wilms' tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes.

    abstract::The Wilms' tumor gene, WT1, is a tumor marker for leukemic blast cells. The WT1 expression levels were examined for 57 patients with myelodysplastic syndromes (MDS) (refractory anemia (RA), 35; RA with excess of blasts (RAEB) 14; RAEB in transformation (RAEB-t), six; and MDS with fibrosis, two) and 12 patients with ac...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401341

    authors: Tamaki H,Ogawa H,Ohyashiki K,Ohyashiki JH,Iwama H,Inoue K,Soma T,Oka Y,Tatekawa T,Oji Y,Tsuboi A,Kim EH,Kawakami M,Fuchigami K,Tomonaga M,Toyama K,Aozasa K,Kishimoto T,Sugiyama H

    更新日期:1999-03-01 00:00:00

  • Reverse transcription polymerase chain reaction is a reliable assay for detecting leukemic colonies generated by chronic myelogenous leukemia cells.

    abstract::Single-colony karyotyping (SCK) and reverse-transcription polymerase chain reaction (RT-PCR) are two increasingly used techniques for the quantification of leukemic colonies generated by chronic myelogenous leukemia (CML) cell fractions purged or selected in vitro. Recently, the existence of Philadelphia (Ph) chromoso...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2400942

    authors: Savoldo B,Sammarelli G,Dotti G,Garau D,Regazzi E,Cilloni D,Tabilio A,Rizzoli V,Carlo-Stella C

    更新日期:1998-03-01 00:00:00

  • Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas.

    abstract::Viral infection induces potent cellular immunity and activated intracellular signaling, which may dictate the driver events involved in immune escape and clonal selection of virus-associated cancers, including Epstein-Barr virus (EBV)-positive lymphomas. Here, we thoroughly interrogated PD-L1/PD-L2-involving somatic a...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-019-0380-5

    authors: Kataoka K,Miyoshi H,Sakata S,Dobashi A,Couronné L,Kogure Y,Sato Y,Nishida K,Gion Y,Shiraishi Y,Tanaka H,Chiba K,Watatani Y,Kakiuchi N,Shiozawa Y,Yoshizato T,Yoshida K,Makishima H,Sanada M,Onozawa M,Teshima T,Yos

    更新日期:2019-07-01 00:00:00

  • Myeloablative therapy with blood stem cell transplantation is effective in mantle cell lymphoma.

    abstract::Long-term disease-free survival following conventional cytotoxic therapy is extremely rare in patients with advanced-stage mantle cell lymphoma (MCL). High-dose conditioning therapy consisting of hyperfractionated total body irradiation (TBI, 14.4 Gy) and cyclophosphamide (200 mg/kg) was therefore offered to 13 patien...

    journal_title:Leukemia

    pub_type: 临床试验,杂志文章

    doi:

    authors: Haas R,Brittinger G,Meusers P,Murea S,Goldschmidt H,Wannenmacher M,Hunstein W

    更新日期:1996-12-01 00:00:00

  • Mesenchymal stromal cells in the antimicrobial host response of hematopoietic stem cell recipients with graft-versus-host disease--friends or foes?

    abstract::Mesenchymal stromal cells (MSCs) are multipotent cells, which exhibit broad immunosuppressive activities. Moreover, they may be administered irrespectively of human leukocyte antigen (HLA) compatibility, without inducing life-threatening immunological reactions, as they express no HLA class II and limited HLA class I ...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/leu.2014.127

    authors: Balan A,Lucchini G,Schmidt S,Schneider A,Tramsen L,Kuçi S,Meisel R,Bader P,Lehrnbecher T

    更新日期:2014-10-01 00:00:00

  • Molecular heterogeneity of sporadic adult Burkitt-type leukemia/lymphoma as revealed by PCR and cytogenetics: correlation with morphology, immunology and clinical features.

    abstract::Chromosomal translocations involving the MYC oncogene are a hallmark of Burkitt lymphoma but they are only found in a varying frequency in mature Burkitt-type acute lymphoblastic leukemia (B-ALL). We have investigated samples of 56 sporadic Burkitt leukemia/lymphoma patients for the translocations t(8;14)(q24;q32), t(...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2403847

    authors: Burmeister T,Schwartz S,Horst HA,Rieder H,Gökbuget N,Hoelzer D,Thiel E

    更新日期:2005-08-01 00:00:00

  • New therapeutic opportunities from dissecting the pre-B leukemia bone marrow microenvironment.

    abstract::The microenvironments of leukemia and cancer are critical for multiple stages of malignancies, and they are an attractive therapeutic target. While skeletal abnormalities are commonly seen in children with acute lymphoblastic leukemia (ALL) prior to initiating osteotoxic therapy, little is known about the alterations ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-018-0144-7

    authors: Cheung LC,Tickner J,Hughes AM,Skut P,Howlett M,Foley B,Oommen J,Wells JE,He B,Singh S,Chua GA,Ford J,Mullighan CG,Kotecha RS,Kees UR

    更新日期:2018-11-01 00:00:00

  • New insight on the role of extrachromosomal retroviral DNA.

    abstract::During infection with different retroviruses, high levels of unintegrated extrachromosomal DNA accumulate in infected cells. While extrachromosomal linear DNA is the immediate precursor of the integrated provirus, the function, if any, of extrachromosomal circular DNA has been unclear. Several groups have attempted to...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/sj.leu.2400776

    authors: Cara A,Reitz MS Jr

    更新日期:1997-09-01 00:00:00

  • Harmonization of molecular monitoring of CML therapy in Europe.

    abstract::The high efficacy of the standard treatment of chronic myeloid leukemia (CML) with imatinib has prompted the need for accurate methods to monitor response at levels below the landmark of complete cytogenetic remission. Quantification of BCR-ABL transcripts has proven to be the most sensitive method available, and has ...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/leu.2009.168

    authors: Müller MC,Cross NC,Erben P,Schenk T,Hanfstein B,Ernst T,Hehlmann R,Branford S,Saglio G,Hochhaus A

    更新日期:2009-11-01 00:00:00

  • Potential involvement of the AML1-MTG8 fusion protein in the granulocytic maturation characteristic of the t(8;21) acute myelogenous leukemia revealed by microarray analysis.

    abstract::The AML1 (RUNX1)-MTG8 (ETO) fusion transcription factor generated by the t(8;21) translocation is believed to deregulate the expression of genes that are crucial for normal differentiation and proliferation of hematopoietic progenitors, resulting in acute myelogenous leukemia. To elucidate the role of AML1-MTG8 in leu...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2402465

    authors: Shimada H,Ichikawa H,Ohki M

    更新日期:2002-05-01 00:00:00

  • Induction of microRNAs, mir-155, mir-222, mir-424 and mir-503, promotes monocytic differentiation through combinatorial regulation.

    abstract::Acute myeloid leukemia (AML) involves a block in terminal differentiation of the myeloid lineage and uncontrolled proliferation of a progenitor state. Using phorbol myristate acetate (PMA), it is possible to overcome this block in THP-1 cells (an M5-AML containing the MLL-MLLT3 fusion), resulting in differentiation to...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2009.246

    authors: Forrest AR,Kanamori-Katayama M,Tomaru Y,Lassmann T,Ninomiya N,Takahashi Y,de Hoon MJ,Kubosaki A,Kaiho A,Suzuki M,Yasuda J,Kawai J,Hayashizaki Y,Hume DA,Suzuki H

    更新日期:2010-02-01 00:00:00

  • VEGF receptors on chronic lymphocytic leukemia (CLL) B cells interact with STAT 1 and 3: implication for apoptosis resistance.

    abstract::We have previously shown that chronic lymphocytic leukemia (CLL) B cells secrete vascular endothelial growth factor (VEGF) in vitro, have constitutively active VEGF receptors R1 and R2, and respond to exogenous VEGF by specifically upregulating Mcl-1 and XIAP in association with decreased cell death. We found that epi...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2403667

    authors: Lee YK,Shanafelt TD,Bone ND,Strege AK,Jelinek DF,Kay NE

    更新日期:2005-04-01 00:00:00

  • Acute myeloid leukemia (AML) having evolved from essential thrombocythemia (ET): distinctive chromosome abnormalities in patients treated with pipobroman or hydroxyurea.

    abstract::ET is a chronic myeloproliferative disorder rarely evolving into AML, sometimes preceded by a myelodysplastic syndrome (MDS). Such transformations mostly occur in patients treated with radiophosphorous ((32)P) or alkylating agents, especially busulfan. Recently, concern has also arisen about the long-term safety of hy...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2402638

    authors: Bernasconi P,Boni M,Cavigliano PM,Calatroni S,Brusamolino E,Passamonti F,Volpe G,Pistorio A,Giardini I,Rocca B,Caresana M,Lazzarino M,Bernasconi C

    更新日期:2002-10-01 00:00:00

  • Translocation t(1;6)(p35.3;p25.2): a new recurrent aberration in "unmutated" B-CLL.

    abstract::Although reciprocal chromosomal translocations are not typical for B-cell chronic lymphocytic leukemia (B-CLL), we identified the novel t(1;6)(p35.3;p25.2) in eight patients with this disorder. Interestingly, all cases showed lack of somatically mutated IgV(H). Clinical, morphological, immunologic, and genetic feature...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2403543

    authors: Michaux L,Wlodarska I,Rack K,Stul M,Criel A,Maerevoet M,Marichal S,Demuynck H,Mineur P,Kargar Samani K,Van Hoof A,Ferrant A,Marynen P,Hagemeijer A

    更新日期:2005-01-01 00:00:00

  • BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells.

    abstract::Myeloproliferative neoplasms with myelofibrosis (MPN-MF) demonstrate constitutive activation of Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling that responds to treatment with the JAK1 and 2 kinase inhibitor (JAKi) ruxolitinib. However, MPN-MF often progresses (~20%) to secondary acu...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2016.260

    authors: Saenz DT,Fiskus W,Manshouri T,Rajapakshe K,Krieger S,Sun B,Mill CP,DiNardo C,Pemmaraju N,Kadia T,Parmar S,Sharma S,Coarfa C,Qiu P,Verstovsek S,Bhalla KN

    更新日期:2017-03-01 00:00:00

  • Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV.

    abstract::Major molecular remission (MMR) is an important therapy goal in chronic myeloid leukemia (CML). So far, MMR is not a failure criterion according to ELN management recommendation leading to uncertainties when to change therapy in CML patients not reaching MMR after 12 months. At monthly landmarks, for different molecul...

    journal_title:Leukemia

    pub_type: 杂志文章,随机对照试验

    doi:10.1038/s41375-018-0055-7

    authors: Saussele S,Hehlmann R,Fabarius A,Jeromin S,Proetel U,Rinaldetti S,Kohlbrenner K,Einsele H,Falge C,Kanz L,Neubauer A,Kneba M,Stegelmann F,Pfreundschuh M,Waller CF,Oppliger Leibundgut E,Heim D,Krause SW,Hofmann WK,Has

    更新日期:2018-05-01 00:00:00

  • Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study.

    abstract::Promising new drugs are being evaluated for treatment of multiple myeloma (MM), but their impact should be measured against the expected outcome in patients failing current therapies. However, the natural history of relapsed disease in the current era remains unclear. We studied 286 patients with relapsed MM, who were...

    journal_title:Leukemia

    pub_type: 杂志文章,多中心研究

    doi:10.1038/leu.2011.196

    authors: Kumar SK,Lee JH,Lahuerta JJ,Morgan G,Richardson PG,Crowley J,Haessler J,Feather J,Hoering A,Moreau P,LeLeu X,Hulin C,Klein SK,Sonneveld P,Siegel D,Bladé J,Goldschmidt H,Jagannath S,Miguel JS,Orlowski R,Palumbo A,

    更新日期:2012-01-01 00:00:00